Dr Reddy's Q1 Results: Profit Slumps 69%, Revenue Declines as Semaglutide Disruption, Weak US Sales Weigh on

Dr Reddy's Laboratories reported a weak set of earnings for the first quarter of FY27, with profit declining sharply due to supply disruptions in its semaglutide business and continued pressure in the US market. The Hyderabad-based drugmaker said its consolidated net profit fell 69% year-on-year to Rs 443 crore for the quarter ended June 30, 2026, compared with Rs 1,418 crore in the same period last year.

Dr Reddy's Q1 Results: Net Profit Slumps 69%, Revenue Declines 5.6%

The company also reported lower revenue during the quarter. Revenue from operations declined 5.6% to Rs 8,070.5 crore, down from Rs 8,545.2 crore in the year-ago period.

Semaglutide Supply Disruption Hits Q1 Earnings

A major reason behind the sharp decline in profit was a Rs 240 crore provision related to semaglutide, a medicine used to treat diabetes and obesity.

Earlier this year, Dr Reddy's had announced that supplies of semaglutide would remain unavailable in India and face disruptions in Canada after quality issues were detected in one of the active pharmaceutical ingredients used to manufacture the drug. The issue forced the company to suspend production of fresh batches, resulting in additional costs during the quarter.

The company said the provision mainly relates to inventory and other expenses arising from the disruption. Semaglutide is considered one of the fastest-growing medicines globally because of rising demand for diabetes treatment and weight management. It is the active ingredient used in several popular obesity and diabetes drugs.

As patents expire in India, many pharmaceutical companies are preparing to introduce generic versions of the medicine. Dr Reddy's is also expected to benefit from this opportunity. However, the current supply disruption may temporarily delay the company's plans to strengthen its presence in this high-growth segment.

North America Revenue Falls 35% Amid Generic Drug Pricing Pressure

Apart from the semaglutide issue, Dr Reddy's also witnessed weakness in its largest overseas market. Revenue from North America declined 35.3% year-on-year to Rs 2,205 crore, mainly because of lower sales of key generic medicines and continued pricing pressure in the US pharmaceutical market.

The company also reported weaker sales of Lenalidomide, its generic version of the cancer drug Revlimid. The product had previously contributed significantly to earnings, but increasing competition has reduced both prices and market share.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.